The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

Bernies van der Hiel,Else A Aalbersberg,Alfons J M van den Eertwegh,Linda J de Wit-van der Veen,Marcel P M Stokkel,Marta Lopez-Yurda,Ronald Boellaard,Ellen W Kapiteijn,Geke A P Hospers,Maureen J B Aarts,Filip Y F L de Vos,Marye J Boers-Sonderen,Astrid A M van der Veldt,Jan Willem B de Groot,John B A G Haanen

Clinical nuclear medicine（2023）

引用 0|浏览9

暂无评分

摘要

This study shows that PERCIST response assessment at week 7 is predictive for PFS, regardless of LDH. At 2 weeks, patients with CMR have longer PFS than patients with non-CMR, but different PET parameters should be investigated to further evaluate the added value of early 18F-FDG PET/CT. Disease progression on PET/CT is predominated by progression of known metastases, and new 18F-FDG-avid lesions during BRAF/MEKi are not automatically a sign of recurrent disease.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要